Similar articles

• Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?".

  Broome DR, Cottrell AC, Kanal E. Broome DR, et al. AJR Am J Roentgenol. 2007 Oct;189(4):W234-5. doi: 10.2214/AJR.07.2919. AJR Am J Roentgenol. 2007. PMID: 17885040 No abstract available.
• Gadodiamide-associated nephrogenic systemic fibrosis.

  Karlik SJ. Karlik SJ. AJR Am J Roentgenol. 2007 Jun;188(6):W584; author reply W585. doi: 10.2214/AJR.07.0177. AJR Am J Roentgenol. 2007. PMID: 17515359 No abstract available.
• Gadolinium-associated nephrogenic systemic fibrosis: double dose, not single dose.

  Ng YY, Lee RC, Shen SH, Kirk G. Ng YY, et al. AJR Am J Roentgenol. 2007 Jun;188(6):W582; author reply W583. doi: 10.2214/AJR.07.0047. AJR Am J Roentgenol. 2007. PMID: 17515358 No abstract available.
• Nephrogenic systemic fibrosis: center case review.

  Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-Parker S, Martin DR. Lauenstein TC, et al. J Magn Reson Imaging. 2007 Nov;26(5):1198-203. doi: 10.1002/jmri.21136. J Magn Reson Imaging. 2007. PMID: 17969162 Review.
• Gadolinium and nephrogenic systemic fibrosis: association or causation.

  Kurtkoti J, Snow T, Hiremagalur B. Kurtkoti J, et al. Nephrology (Carlton). 2008 Jun;13(3):235-41. doi: 10.1111/j.1440-1797.2007.00912.x. Epub 2008 Jan 23. Nephrology (Carlton). 2008. PMID: 18221255 Review.